Nuclear Medicine Communications最新文献

{"title":"PET/CT-based deep learning for differentiating squamous cell carcinoma from adenocarcinoma in non-small cell lung cancer: comparison of multimodal fusion strategies.","authors":"Gang Yan, Na Hu, Mengjuan Ran, Shuzhen Liu, Guijuan Han, Luying Xu, Rongmei Li, Qinghong Duan","doi":"10.1097/MNM.0000000000002236","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002236","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate 18F-fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT)-based deep learning for differentiating squamous cell carcinoma (SqCC) from adenocarcinoma (ADC) in non-small cell lung cancer (NSCLC) and to compare single-modality and multimodal fusion strategies.</p><p><strong>Methods: </strong>This retrospective study included 220 patients with pathologically confirmed NSCLC (86 SqCC and 134 ADC) who underwent pretreatment 18F-FDG PET/CT. A 2.5D input strategy used the axial tumor slice with the largest mask area and its two adjacent slices. Four models were developed: PET-only, CT-only, PET/CT dual-branch fusion, and PET/CT six-channel early fusion. Performance was evaluated using five-fold stratified cross-validation with area under the receiver operating characteristic curve (AUC), accuracy, balanced accuracy, sensitivity, specificity, F1-score, and Matthews correlation coefficient (MCC).</p><p><strong>Results: </strong>The PET-only model achieved higher mean AUC and MCC than the CT-only model. The PET/CT six-channel early fusion model achieved the highest mean AUC (0.766 ± 0.082), balanced accuracy (0.765 ± 0.071), specificity (0.882 ± 0.093), and MCC (0.530 ± 0.132). The dual-branch fusion model achieved the highest mean sensitivity (0.755 ± 0.144), although its mean AUC was lower than that of the PET-only model.</p><p><strong>Conclusion: </strong>PET/CT six-channel early fusion showed potential for differentiating ADC from SqCC and may provide complementary information for noninvasive histological assessment. External validation is required before clinical application.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney impairment post 177Lu-PSMA radioligand therapy in metastatic prostate cancer.","authors":"Jesse Osbourne, Michael S Hofman, Irene Ruderman","doi":"10.1097/MNM.0000000000002243","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002243","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is a novel theranostic approved for the treatment of metastatic castration-resistant prostate cancer. It has been understood to have a low risk of mild nephrotoxicity, although the emergence of delayed or acute renal toxicity is variably described. The increasing use of PSMA-RLT as an earlier line of therapy has prompted a review of its renal safety. Given substantial heterogeneity in study design, follow-up, and outcome definitions, findings were synthesized narratively following the Synthesis without Meta-analysis guideline rather than pooled quantitatively. Studies were grouped by evidence hierarchy (randomized, prospective single-arm, retrospective/real-world, and case report/series) before synthesis. Risk of bias was assessed using design-appropriate tools (Cochrane Risk of Bias 2; a five-domain quality-scoring rubric; Joanna Briggs Institute principles for case reports). A review of 45 papers demonstrated mild nephrotoxicity (estimate glomerular filtration rate: 30-<90 mL/min/1.73m2) post-PSMA-RLT. Where chronic kidney disease (CKD) developed, it was either delayed in onset and progressive over time. There was broad heterogeneity of patient cohorts, methodologies, and data quality. In addition, there was limited long-term follow-up data regarding chronic nephrotoxicity, with only five studies having follow-up periods >12 months after the last treatment cycle. While incidence varied, the severity of renal impairment was commonly mild. The true rate of long-term renal injury is potentially underestimated as endpoints are inconsistently defined, baseline CKD risk is variably reported, and follow-up is often short. Future research with extended follow-up periods beyond 12 months is warranted to understand the true rate of CKD development.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"18F-FDG PET/CT radiomics for prediction of BRCA mutations in high-grade serous ovarian cancer.","authors":"Fangmei Jiang, Shuyong Liu, Chunli Liu, Wenrui Zhang, Xinyan Liu, Xiang Wu, Juan Xu, Ruoyao Zou","doi":"10.1097/MNM.0000000000002245","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002245","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop and validate a 18F-fluorodeoxyglucose PET/computed tomography (CT)-based radiomics model for predicting BRCA mutation status in patients with advanced high-grade serous ovarian cancer (HGSOC).</p><p><strong>Methods: </strong>A retrospective study of 124 patients with HGSOC who underwent preoperative PET/CT scans and BRCA mutation testing was conducted. The cohort was divided into training and internal validation sets using a 7 : 3 ratio. An external validation set of 25 patients was used to confirm model generalizability. Radiomic features were extracted from PET and CT images and used to build predictive models using logistic regression, random forest, support vector machine, and decision tree classifiers. The models were evaluated for their predictive performance using metrics such as the area under the receiver operating characteristic curve (AUC), accuracy, precision, sensitivity, and F1 score. A combined model incorporating radiomics, PET/CT metabolic parameters, and clinical variables was also constructed. In addition, the radiomics models were used to predict progression-free survival (PFS) and overall survival in the training and internal validation cohorts.</p><p><strong>Results: </strong>The logistic regression model showed the best performance, with AUCs of 94.79, 87.37, and 85.06% in the training, internal, and external validation cohorts, respectively. The combined model achieved the highest AUCs of 0.968, 0.932, and 0.960 in the training, internal validation, and external validation cohorts, respectively. Significant differences in PFS between risk groups were observed, while overall survival differences were not statistically significant.</p><p><strong>Conclusion: </strong>The PET/CT-based radiomics model accurately predicts BRCA mutation status in HGSOC, potentially aiding in personalized treatment strategies.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive acceptance testing and quality control of Single Photon Emission Computed Tomography/Computed Tomography systems.","authors":"Noor Ul Huda Abbasi, Hannan Younis, Saeed Ur Rehman, Burhan Zia Abbasi, Roya Feroze, Khurram Mehboob, Muhammad Ajaz","doi":"10.1097/MNM.0000000000002240","DOIUrl":"10.1097/MNM.0000000000002240","url":null,"abstract":"<p><strong>Background: </strong>Single photon emission computed tomography/computed tomography (SPECT/CT) systems play a crucial role in nuclear medicine for accurate diagnosis and treatment planning. Ensuring high image quality through rigorous acceptance testing and quality control is essential to maintain diagnostic reliability and patient safety.</p><p><strong>Objective: </strong>This study evaluated the performance of SPECT/CT systems at NORI Hospital Islamabad against National Electrical Manufacturers Association (NEMA) and International Atomic Energy Agency standards and developed a structured quality control program based on acceptance testing results.</p><p><strong>Methods: </strong>Acceptance tests were carried out using Tc-99m, I-131, and Co-57 radioactive sources, in conjunction with quadrant bar and Jaszczak phantoms. Parameters assessed included spatial resolution, intrinsic and extrinsic uniformity, energy resolution, sensitivity, center of rotation (COR), detector shielding, background counts, leakage, CT number accuracy, and nuclear medicine/CT registration. Data were compared with manufacturer specifications and NEMA standards to evaluate system performance and inform quality control strategies.</p><p><strong>Results: </strong>Both detectors exhibited intrinsic and extrinsic uniformity within NEMA limits, ensuring consistent image quality. Spatial resolution testing confirmed sharp and precise imaging, while energy resolution was within manufacturer-specified values. Sensitivity measurements showed minor differences between detectors but remained within acceptable ranges. COR values were precise (<±0.55 mm), confirming proper mechanical and software alignment. CT number accuracy and nuclear medicine/CT registration tests confirmed precise anatomical-functional image overlay. Detector shielding and leakage tests showed minimal interference, supporting reliable imaging.</p><p><strong>Conclusion: </strong>The SPECT/CT systems at NORI Hospital Islamabad met established NEMA standards for image quality. Acceptance testing validated detector performance and highlighted minor areas for improvement, such as periodic sensitivity calibration. Implementation of a structured quality control program ensures consistent equipment performance, optimal image quality, improved diagnostic accuracy, and superior patient care. Routine adherence to international standards is essential for maintaining high-quality nuclear medicine imaging practices.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatic reticuloendothelial distribution on sulfur colloid single-photon emission computed tomography/computed tomography is discordant with biochemical liver function in patients undergoing preradioembolization evaluation.","authors":"Syed Hasan Raza, Zachary Nuffer, Neal Savjani, Ayman Farag, Arash Kardan","doi":"10.1097/MNM.0000000000002241","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002241","url":null,"abstract":"<p><strong>Objective: </strong>To determine whether qualitative technetium-99m sulfur colloid (99mTc-SC) single-photon emission computed tomography/computed tomography (SPECT/CT) grading is discordant with conventional liver function assessment in patients undergoing preradioembolization evaluation.</p><p><strong>Methods: </strong>This single-center retrospective study included 96 consecutive patients who underwent dual-tracer 99mTc-macroaggregated albumin and 99mTc-SC SPECT/CT for yttrium-90 transarterial radioembolization planning. Sulfur colloid uptake was graded visually on a three-tier ordinal scale: grade I, normal; grade II, intermediate; and grade III, colloid shift. Contemporaneous laboratory values, Child-Pugh class, and model for end-stage liver disease score were recorded. Concordance was assessed using weighted kappa. Associations were evaluated with Spearman correlation, receiver operating characteristic analysis, and ordinal logistic regression.</p><p><strong>Results: </strong>Abnormal sulfur colloid findings, defined as grade II/III uptake, were present in 19 of 96 patients (19.8%), including eight patients (8.3%) with grade III colloid shift. Among 85 Child-Pugh A patients, 15 (17.6%) had abnormal sulfur colloid uptake; among 70 lab-normal patients, 11 (15.7%) had abnormal sulfur colloid uptake. Agreement between sulfur colloid grade and Child-Pugh class was poor (weighted kappa: 0.142). Higher sulfur colloid grade correlated modestly with albumin, total bilirubin, international normalized ratio, aspartate aminotransferase, and creatinine, but no variable remained independently associated after adjustment. Albumin best discriminated grade III shift [area under the curve (AUC): 0.732], whereas Child-Pugh class performed near chance (AUC: 0.511).</p><p><strong>Conclusion: </strong>Sulfur colloid SPECT/CT demonstrates reticuloendothelial distribution abnormalities in approximately one-fifth of preradioembolization patients, including some with preserved biochemical function. These discordant findings support further outcome-anchored evaluation of sulfur colloid SPECT/CT as a complementary tool before Y-90 radioembolization.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148990913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorodeoxyglucose PET/CT-derived Metabolic Peritoneal Cancer Index for survival assessment in peritoneal carcinomatosis.","authors":"Semra Demirtaş Şenlik, Alev Noyaner Çinar, Ceren Özge Engür Uyanik, Ayşenur Erdem Karaoğlu, Osman Sütçüoğlu, Berna Öksüzoğlu, Özlem Özmen","doi":"10.1097/MNM.0000000000002244","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002244","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between the Metabolically active Peritoneal Cancer Index (M-PCI) derived from 18F-fluorodeoxyglucose PET/computed tomography (18F-FDG PET/CT) and to assess its ability to predict overall survival (OS) in patients with peritoneal carcinomatosis.</p><p><strong>Methods: </strong>This retrospective study included 107 patients with pathologically confirmed peritoneal carcinomatosis who underwent 18F-FDG PET/CT between October 2022 and July 2025. M-PCI was calculated using a PET-adapted Peritoneal Cancer Index approach based on metabolically active peritoneal lesions across 13 anatomical regions. Patients were stratified using an M-PCI cutoff value of 20, with the appropriateness of this threshold additionally explored using receiver operating characteristic analysis. Survival analysis was performed using Kaplan-Meier analysis and univariable and multivariable Cox regression models.</p><p><strong>Results: </strong>During a median follow-up of 22 months, 78 deaths (72.9%) occurred. The median OS was 9 months. M-PCI was significantly associated with OS [hazard ratio = 1.050 per unit increase; 95% confidence interval (CI) = 1.019-1.082; P = 0.001]. Patients with M-PCI > 20 had significantly worse survival compared with those with M-PCI ≤ 20 (median OS = 3 vs. 10 months; log-rank P = 0.010), with nearly a two-fold increase in mortality risk (hazard ratio = 1.94; 95% CI = 1.14-3.32; P = 0.015). The prognostic impact of M-PCI was particularly pronounced in the gynecologic subgroup. In multivariable Cox regression analysis, M-PCI remained independently associated with OS after adjustment for tumor origin, treatment, extent of disease, ascites, and timing of peritoneal carcinomatosis (adjusted hazard ratio = 1.040; 95% CI = 1.002-1.080; P = 0.042).</p><p><strong>Conclusion: </strong>M-PCI derived from 18F-FDG PET/CT is a significant predictor of OS in patients with peritoneal carcinomatosis. By integrating metabolic activity with spatial disease distribution, M-PCI may provide clinically relevant prognostic information and improve risk stratification in this patient population.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of risk organ involvement and metabolic parameters assessed by staging 18F-FDG PET/CT in pediatric Langerhans cell histiocytosis.","authors":"İpek Öztürk, Selin Gül Yaran, Özgü Hançerli, Enes Mustafa Kaya, Ali Ayçiçek, Meryem Kaya, Burcu Esen Akkaş","doi":"10.1097/MNM.0000000000002242","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002242","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prognostic impact of risk organ involvement and baseline metabolic activity assessed by staging 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in newly diagnosed pediatric Langerhans cell histiocytosis (LCH).</p><p><strong>Methods: </strong>Thirty-two children with histologically confirmed LCH who underwent baseline 18F-FDG PET/CT were retrospectively analyzed. Age, disease extent (single-system vs. multisystem), risk organ involvement (RO- vs. RO+), and baseline metabolic parameters [maximum standardized uptake value (SUVmax), SUVmean, metabolic tumor volume, total lesion glycolysis (TLG), and tumor-to-background ratio (TBR)] were evaluated for their association with progression or relapse. Optimal cut-offs were derived from receiver operating characteristic analysis (Youden index). Survival outcomes were analyzed using Kaplan-Meier and Cox regression models.</p><p><strong>Results: </strong>Over a median follow-up of 33 months, disease progression or relapse occurred in 13 patients (40.6%) and was significantly associated with younger age (P = 0.040), higher SUVmax (P = 0.016), higher TBR (P = 0.007), and TLG (P = 0.033), multisystem LCH (P = 0.004), and risk organ positivity (P < 0.001). Risk-organ involvement was the strongest univariate predictor of adverse outcome (hazard ratio: 14.9, 95% confidence interval: 3.3-67; P < 0.001).</p><p><strong>Conclusion: </strong>Baseline 18F-FDG PET/CT provides important prognostic information in pediatric LCH, with risk organ involvement emerging as the strongest univariate prognostic factor in this cohort, supporting its role in early risk stratification, suggesting a potential role in future risk-adapted treatment planning. Higher SUVmax, TBR, and TLG were associated with progression/relapse in group comparisons, whereas only SUVmax and TBR were significantly associated with progression-free survival in univariate Cox analysis.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of metabolic and tumor dissemination parameters in diffuse large B-cell lymphoma: can relapse be predicted despite adequate interim PET response?","authors":"Ezgi Basak Erdogan, Yusuf Yildiz, Ennur Ramadan, Ozlem Toluk, Mehmet Aydin, Guven Cetin","doi":"10.1097/MNM.0000000000002238","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002238","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate associations of baseline and interim fluorine-18 fluorodeoxyglucose PET/computed tomography parameters with early clinical outcomes in diffuse large B-cell lymphoma (DLBCL) and identify prognostic/predictive biomarkers, including predictors of discordance between interim PET (iPET) response and clinical outcome.</p><p><strong>Methods: </strong>We retrospectively analyzed 112 patients with DLBCL. Baseline clinical/biochemical data and metabolic parameters from staging PET (sPET) and iPET were recorded, and delta (Δ) parameters were calculated. iPET response was classified by Deauville criteria, while follow-up outcomes were categorized as remission or refractory/progressive disease. Group comparisons and receiver operating characteristic analyses were performed.</p><p><strong>Results: </strong>iPET predicted outcomes with 79% sensitivity, 71% specificity, 74% accuracy, 82% negative predictive value, and 66% positive predictive value. Baseline dissemination metrics, including maximum distance between the two most distant lesions and maximum distance between the outermost voxels of the two most distant lesions PET (DmaxVoxPET), were higher in patients developing relapse/progression despite adequate iPET response [area under the curve (AUC): 0.81 and 0.77]; iPET-derived metabolic parameters - maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), peak standardized uptake value (SUVpeak), lesion-to-liver ratio (RLL), total lesion glycolysis, and ΔSUVmax, ΔSUVmean, ΔSUVpeak, and ΔRLL significantly predicted remission (AUC: 0.70-0.79), generally outperforming baseline parameters. SUV-based indices and RLL outperformed TLG, while SUV metrics performed comparably. Ferritin was the only predictive clinical/biochemical variable (AUC: 0.79). According to multivariate logistic regression analysis, advanced-stage disease (P = 0.002) and elevated ferritin levels (P = 0.009) were found to be independent risk factors for disease progression.</p><p><strong>Conclusion: </strong>iPET provides robust early response assessment and stronger predictive value than sPET in DLBCL, particularly through SUV-based parameters and RLL. While sPET reflects tumor burden and dissemination, baseline dissemination metrics may identify patients at risk of relapse despite favorable iPET findings, supporting risk-adapted management and closer surveillance.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148920301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective study of dynamic imaging acquisition length optimisation for sentinel lymph node scans.","authors":"Jan M Walukiewicz, Dave Ashworth, Heather Ann Williams","doi":"10.1097/MNM.0000000000002169","DOIUrl":"10.1097/MNM.0000000000002169","url":null,"abstract":"<p><p>Current guidance recommends dynamic imaging immediately post radiopharmaceutical injection for sentinel lymph node (SLN) scans. However, there is limited information on the recommended acquisition duration. We aimed to determine the time during a 30 min dynamic acquisition at which no additional SLNs were detected, and evaluate how applying a 20 min cut-off influenced clinical interpretation when considering all retrospectively acquired standard-of-care imaging. We retrospectively reviewed 106 SLN dynamic acquisitions for five primary sites: head and neck (19), limb (21), trunk (24), penis (21), and vulva (21). A qualified reporter identified studies in which lymph nodes appeared beyond 15 min. These datasets were independently reviewed by two expert reporters to find the time-point when no further SLNs were observed, and to evaluate differences in the number and location of identified SLNs using a 20-min protocol. We also conducted a survey of centres providing an SLN service to document the current practice of dynamic scan durations for contextual background. Across all studies, no new SLNs were detected after 25 min. When considering all acquired images, a 20 min dynamic identified the same SLNs. Interobserver agreement between expert reporters was 0.82 (95% confidence interval: 0.61-0.93). The eight survey responses revealed a median dynamic duration of 15 min (interquartile range: 13-28 min). While a 25 min dynamic captured all SLNs for all studies, incorporating reporting with all retrospectively acquired standard-of-care imaging indicates a 20 min dynamic duration appears unlikely to alter image reporting. Adopting a 20 min dynamic would reduce clinical workload and improve patient comfort without detriment to image interpretation.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1111-1116"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147777930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining bone metastasis imaging in breast cancer: whole body low-dose computed tomography compared with skeletal scintigraphy in a real-world cohort.","authors":"Lipton Mitra, Ankur Goyal, Nivedita Kundu, Shivam Pandey, Mohit Joshi, K P Haresh, H K Bhattacharjee, Raju Sharma, Rajinder Parshad, Suhani","doi":"10.1097/MNM.0000000000002172","DOIUrl":"10.1097/MNM.0000000000002172","url":null,"abstract":"<p><strong>Background: </strong>Skeletal scintigraphy is standard imaging to detect bone metastasis in breast cancer. Nuclear medicine facilities are limited in availability. As an alternative diagnostic modality, we evaluated whole-body low dose computed tomography (WBLDCT) scan for detection of bone metastasis.</p><p><strong>Methods: </strong>This cross-sectional exploratory study was conducted from November 2021 to May 2023 with an aim to study the clinical applicability of WBLDCT for detecting bone metastasis in patients with breast cancer. Patients with primary tumor measuring 5 cm or more, pathologically proven axillary lymph node metastasis, Stage III/IV disease, symptoms attributable to metastasis and suspected disease recurrence were included. Patients underwent WBLDCT and bone scan within 2 weeks. WBLDCT was done during the same time as conventional dose CT scan done as part of metastatic workup. Image analysis was performed by radiology and nuclear medicine experts in blinded fashion. Agreement amongst WBLDCT, bone scan and combination of these was calculated using inter-rater agreement.</p><p><strong>Results: </strong>One hundred seven patients underwent WBLDCT and bone scan. The mean age was 48.5 years and three-fourth had Stage III disease. Both bone scan and WBLDCT detected bone metastasis in 19 patients. Bone scan picked up additional metastasis in two patients. WBLDCT detected bone metastasis additionally in three patients. Specificity of bone scan and WBLDCT was 87.5 and 91.7%, respectively. Concordance rate of bone scan and WBLDCT with the combination was 0.889 and 0.945, respectively.</p><p><strong>Conclusion: </strong>WBLDCT can be used as an alternative imaging modality to detect bone metastasis in breast cancer patients.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1014-1020"},"PeriodicalIF":1.4,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147841315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}